Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Return on Equity (2017 - 2025)

Spero Therapeutics (SPRO) has disclosed Return on Equity for 9 consecutive years, with 1.45% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Equity fell 149.0% year-over-year to 1.45%, compared with a TTM value of 1.45% through Sep 2025, down 149.0%, and an annual FY2024 reading of 0.9%, down 115.0% over the prior year.
  • Return on Equity was 1.45% for Q3 2025 at Spero Therapeutics, up from 1.62% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.3% in Q4 2023 and bottomed at 2.78% in Q3 2022.
  • Average Return on Equity over 5 years is 0.85%, with a median of 0.78% recorded in 2021.
  • The sharpest move saw Return on Equity plummeted -200bps in 2022, then skyrocketed 268bps in 2023.
  • Year by year, Return on Equity stood at 0.88% in 2021, then grew by 5bps to 0.84% in 2022, then soared by 135bps to 0.3% in 2023, then plummeted by -517bps to 1.23% in 2024, then dropped by -18bps to 1.45% in 2025.
  • Business Quant data shows Return on Equity for SPRO at 1.45% in Q3 2025, 1.62% in Q2 2025, and 1.75% in Q1 2025.